{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T09:35:33Z","timestamp":1793352933167,"version":"4.5.0"},"reference-count":25,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"8","license":[{"start":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T00:00:00Z","timestamp":1781827200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,12]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Head-to-head comparisons of contemporary drug-eluting stents (DES) in patients with acute myocardial infarction (AMI) remain limited. We sought to compare the long-term clinical outcomes of four widely used DES platforms: Orsiro, Xience, Synergy, and Resolute.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      From the nationwide prospective Korea acute myocardial infarction registry-V, we identified 9284 patients with AMI undergoing percutaneous coronary intervention with one of the four study devices (Orsiro,\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      \u2005=\u20051634; Xience,\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      \u2005=\u20052576; Synergy,\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      \u2005=\u20052811; Resolute,\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      \u2005=\u20052263). The primary endpoint was target lesion revascularization (TLR). Inverse probability of treatment weighting was performed to adjust for baseline differences.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      During a median follow-up of 723 days, the cumulative incidence of TLR differed significantly among groups. In IPTW-adjusted analyses, compared with the Orsiro group (reference), the risk of TLR was significantly higher in the Synergy [hazard ratio: 2.30; 95% confidence interval (CI): 1.20\u20134.41,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2005=\u20050.013] and Resolute groups (hazard ratio: 2.30, 95% CI: 1.18\u20134.47,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2005=\u20050.014). The Xience group showed a comparable risk of TLR to Orsiro (hazard ratio: 1.40, 95% CI: 0.69\u20132.82,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2005=\u20050.346). Target vessel revascularization followed a similar pattern, favoring Orsiro. However, there were no significant differences in composite major adverse cardiovascular events or all-cause mortality among the four groups.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In this large-scale, real-world AMI cohort, the ultrathin-strut, biodegradable-polymer Orsiro stent was associated with a lower risk of repeat revascularization compared with the Synergy and Resolute stents. Xience demonstrated comparable outcomes to Orsiro. Stent selection remains a crucial determinant of vessel-level outcomes in patients with AMI.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/mca.0000000000001659","type":"journal-article","created":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T15:00:10Z","timestamp":1781794810000},"page":"606-616","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Comparative effectiveness of Orsiro, Xience, Synergy, and Resolute stent in patients with acute myocardial infarction undergoing percutaneous coronary intervention: a nationwide registry study"],"prefix":"10.1097","volume":"37","author":[{"given":"Hyun Woong","family":"Park","sequence":"first","affiliation":[{"name":"Division of Cardiology, Department of Internal Medicine, Chungnam National University School of Medicine, Chungnam National University Hospital, Daejeon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong Kyun","family":"Kim","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Internal Medicine, Chungnam National University School of Medicine, Chungnam National University Sejong Hospital, Sejong"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seok-Woo","family":"Seong","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Internal Medicine, Chungnam National University School of Medicine, Chungnam National University Hospital, Daejeon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jae-Hwan","family":"Lee","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Internal Medicine, Chungnam National University School of Medicine, Chungnam National University Hospital, Daejeon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mi Joo","family":"Kim","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Internal Medicine, Chungnam National University School of Medicine, Chungnam National University Hospital, Daejeon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pil Sang","family":"Song","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Internal Medicine, Chungnam National University School of Medicine, Chungnam National University Hospital, Daejeon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seon-Ah","family":"Jin","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Internal Medicine, Chungnam National University School of Medicine, Chungnam National University Hospital, Daejeon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kye Taek","family":"Ahn","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Internal Medicine, Chungnam National University School of Medicine, Chungnam National University Hospital, Daejeon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youngkeun","family":"Ahn","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Internal Medicine, Heart Center, Chonnam National University Hospital, Chonnam National University Medical School, Gwangju"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sang Hyun","family":"Park","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine and Cardiovascular Center, Daejeon Eulji University Hospital, Daejeon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin-Yong","family":"Hwang","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Gyeongsang National University School of Medicine, Gyeongsang National University Hospital, Jinju"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang-Hwan","family":"Yoon","sequence":"additional","affiliation":[{"name":"Seoul National University Bundang Hospital, Seongnam-si, Gyeonggi-do, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin-Ok","family":"Jeong","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Internal Medicine, Chungnam National University School of Medicine, Chungnam National University Hospital, Daejeon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"KAMIR Investigators","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,6,19]]},"reference":[{"key":"R1-20261030","doi-asserted-by":"crossref","first-page":"e21","DOI":"10.1016\/j.jacc.2021.09.006","article-title":"2021 ACC\/AHA\/SCAI guideline for coronary artery revascularization: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines.","volume":"79","author":"Lawton","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"R2-20261030","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1056\/NEJMra1210816","article-title":"Drug-eluting coronary-artery stents.","volume":"368","author":"Stefanini","year":"2013","journal-title":"N Engl J Med"},{"key":"R3-20261030","doi-asserted-by":"crossref","first-page":"2873","DOI":"10.1161\/CIRCULATIONAHA.112.097014","article-title":"Short- and long-term outcomes with drug-eluting and bare-metal coronary stents: a mixed-treatment comparison analysis of 117 762 patient-years of follow-up from randomized trials.","volume":"125","author":"Bangalore","year":"2012","journal-title":"Circulation"},{"key":"R4-20261030","doi-asserted-by":"crossref","first-page":"3320","DOI":"10.1093\/eurheartj\/ehv511","article-title":"Stent thrombosis and restenosis: what have we learned and where are we going? The Andreas Gruntzig Lecture ESC 2014.","volume":"36","author":"Byrne","year":"2015","journal-title":"Eur Heart J"},{"key":"R5-20261030","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1093\/eurheartj\/ehaa575","article-title":"2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation.","volume":"42","author":"Collet","year":"2021","journal-title":"Eur Heart J"},{"key":"R6-20261030","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.4244\/EIJ-D-16-00179","article-title":"Angiographic outcomes of Orsiro biodegradable polymer sirolimus-eluting stents and Resolute Integrity durable polymer zotarolimus-eluting stents: results of the ORIENT trial.","volume":"12","author":"Kang","year":"2017","journal-title":"EuroIntervention"},{"key":"R7-20261030","doi-asserted-by":"crossref","first-page":"e002230","DOI":"10.1161\/CIRCINTERVENTIONS.114.002230","article-title":"Comparison of zotarolimus- and everolimus-eluting coronary stents: final 5-year report of the RESOLUTE all-comers trial.","volume":"8","author":"Iqbal","year":"2015","journal-title":"Circ Cardiovasc Interv"},{"key":"R8-20261030","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1016\/S0140-6736(19)31877-X","article-title":"Biodegradable polymer sirolimus-eluting stents versus durable polymer everolimus-eluting stents in patients with ST-segment elevation myocardial infarction (BIOSTEMI): a single-blind, prospective, randomised superiority trial.","volume":"394","author":"Iglesias","year":"2019","journal-title":"Lancet"},{"key":"R9-20261030","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1253\/circj.CJ-16-0061","article-title":"Multicenter cohort study of acute myocardial infarction in Korea - Interim analysis of the Korea acute myocardial infarction registry-national institutes of health registry.","volume":"80","author":"Kim","year":"2016","journal-title":"Circ J"},{"key":"R10-20261030","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1161\/CIRCULATIONAHA.110.003210","article-title":"Stent thrombogenicity early in high-risk interventional settings is driven by stent design and deployment and protected by polymer-drug coatings.","volume":"123","author":"Kolandaivelu","year":"2011","journal-title":"Circulation"},{"key":"R11-20261030","doi-asserted-by":"crossref","first-page":"e0209841","DOI":"10.1371\/journal.pone.0209841","article-title":"Comparisons of early vascular reactions in biodegradable and durable polymer-based drug-eluting stents in the porcine coronary artery.","volume":"14","author":"Ijichi","year":"2019","journal-title":"PLoS One"},{"key":"R12-20261030","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.jacc.2006.03.042","article-title":"Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk.","volume":"48","author":"Joner","year":"2006","journal-title":"J Am Coll Cardiol"},{"key":"R13-20261030","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1093\/eurheartj\/ehs036","article-title":"Comparison of drug-eluting stents with bare metal stents in patients with ST-segment elevation myocardial infarction.","volume":"33","author":"Kalesan","year":"2012","journal-title":"Eur Heart J"},{"key":"R14-20261030","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1161\/CIRCINTERVENTIONS.113.000415","article-title":"Outcomes with various drug-eluting or bare metal stents in patients with ST-segment-elevation myocardial infarction: a mixed treatment comparison analysis of trial level data from 34 068 patient-years of follow-up from randomized trials.","volume":"6","author":"Bangalore","year":"2013","journal-title":"Circ Cardiovasc Interv"},{"key":"R15-20261030","doi-asserted-by":"crossref","first-page":"2503","DOI":"10.1016\/S0140-6736(19)30474-X","article-title":"Drug-eluting or bare-metal stents for percutaneous coronary intervention: a systematic review and individual patient data meta-analysis of randomised clinical trials.","volume":"393","author":"Piccolo","year":"2019","journal-title":"Lancet"},{"key":"R16-20261030","doi-asserted-by":"crossref","first-page":"2223","DOI":"10.1056\/NEJMoa1610227","article-title":"Everolimus-eluting stents or bypass surgery for left main coronary artery disease.","volume":"375","author":"Stone","year":"2016","journal-title":"N Engl J Med"},{"key":"R17-20261030","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1056\/NEJMoa1004130","article-title":"Comparison of zotarolimus-eluting and everolimus-eluting coronary stents.","volume":"363","author":"Serruys","year":"2010","journal-title":"N Engl J Med"},{"key":"R18-20261030","doi-asserted-by":"crossref","first-page":"2111","DOI":"10.1016\/S0140-6736(14)61038-2","article-title":"Ultrathin strut biodegradable polymer sirolimus-eluting stent versus durable polymer everolimus-eluting stent for percutaneous coronary revascularisation (BIOSCIENCE): a randomised, single-blind, non-inferiority trial.","volume":"384","author":"Pilgrim","year":"2014","journal-title":"Lancet"},{"key":"R19-20261030","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1016\/S0140-6736(17)32249-3","article-title":"Ultrathin, bioresorbable polymer sirolimus-eluting stents versus thin, durable polymer everolimus-eluting stents in patients undergoing coronary revascularisation (BIOFLOW V): a randomised trial.","volume":"390","author":"Kandzari","year":"2017","journal-title":"Lancet"},{"key":"R20-20261030","doi-asserted-by":"crossref","first-page":"e002372","DOI":"10.1161\/CIRCINTERVENTIONS.114.002372","article-title":"Efficacy and safety of a novel bioabsorbable polymer-coated, everolimus-eluting coronary stent: the EVOLVE II randomized trial.","volume":"8","author":"Kereiakes","year":"2015","journal-title":"Circ Cardiovasc Interv"},{"key":"R21-20261030","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.4244\/EIJ-D-17-00271","article-title":"A randomised comparison of biodegradable polymer- and permanent polymer-coated platinum-chromium everolimus-eluting coronary stents in China: the EVOLVE China study.","volume":"13","author":"Han","year":"2017","journal-title":"EuroIntervention"},{"key":"R22-20261030","doi-asserted-by":"crossref","first-page":"3113","DOI":"10.1016\/j.jacc.2017.10.036","article-title":"Quality-of-life after everolimus-eluting stents or bypass surgery for left-main disease: results from the excel trial.","volume":"70","author":"Baron","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"R23-20261030","doi-asserted-by":"crossref","first-page":"e003803","DOI":"10.1161\/JAHA.116.003803","article-title":"Comparison of vascular responses following new-generation biodegradable and durable polymer-based drug-eluting stent implantation in an atherosclerotic rabbit iliac artery model.","volume":"5","author":"Nakazawa","year":"2016","journal-title":"J Am Heart Assoc"},{"key":"R24-20261030","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/s12928-021-00777-4","article-title":"A serial optical frequency-domain imaging study of early and late vascular responses to bioresorbable-polymer sirolimus-eluting stents for the treatment of acute myocardial infarction and stable coronary artery disease patients: results of the MECHANISM-ULTIMASTER study.","volume":"37","author":"Itoh","year":"2022","journal-title":"Cardiovasc Interv Ther"},{"key":"R25-20261030","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.4244\/EIJ-D-21-00192","article-title":"Temporal trends in clinical outcomes after percutaneous coronary intervention: a systematic review of 66,327 patients from 25 all-comers trials.","volume":"17","author":"Asano","year":"2022","journal-title":"EuroIntervention"}],"container-title":["Coronary Artery Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/MCA.0000000000001659","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T09:01:20Z","timestamp":1793350880000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/MCA.0000000000001659"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,19]]},"references-count":25,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/mca.0000000000001659","relation":{},"ISSN":["0954-6928","1473-5830"],"issn-type":[{"value":"0954-6928","type":"print"},{"value":"1473-5830","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,19]]},"assertion":[{"value":"2026-02-12","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-05-16","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}